piracetam has been researched along with Amnesia in 47 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Amnesia: Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of piracetam on the amnesias induced by scopolamine, diazepam and electroconvulsive shock (ECS) were studied in a passive avoidance procedure in the mouse and compared with the interactions of piracetam with the major behavioral effects of these treatments, namely scopolamine-induced hyperactivity, diazepam-induced release of punished behavior (Four Plates Test) and ECS-induced convulsions." | 7.67 | Specificity of piracetam's anti-amnesic activity in three models of amnesia in the mouse. ( Avril, I; Chermat, R; Lenègre, A; Porsolt, RD; Stéru, L, 1988) |
| " Active compounds exhibited an inverted U-shaped dose-response curve." | 5.27 | Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam. ( Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L, 1984) |
| " Elevated plus-maze and passive-avoidance apparatus served as the exteroceptive behavioral models, and diazepam-, scopolamine-, and aging-induced amnesia served as the interoceptive behavioral models." | 3.72 | Ascorbic Acid: a promising memory-enhancer in mice. ( Dhingra, D; Parle, M, 2003) |
| "The model of amnestic syndrome obtained by treatment with scopolamine during 20 days in rats was used to study anti-amnesic activity of amiridin in comparison with that of tacrine, physostigmine and piracetam." | 3.68 | [Study of anti-amnesic activity of amiridin in a model of amnesic syndrome]. ( Burov, IuV; Kadysheva, LV; Robakidze, TN; Shaposhnikova, GI; Voronin, AE, 1991) |
| " The cognition activating properties of lactams 4, 5, 6, and 10 were evaluated in enhancing retention for passive avoidance learning in rats without and after electroconvulsive shock (ECS); compounds 5 and 10 were found to be more potent than piracetam in the amnesia-reversal testing." | 3.67 | Synthesis and cognition activating properties of some mono- and bicyclic lactam derivatives. ( Altomare, C; Carotti, A; Casini, G; Cellamare, S; Ferappi, M; Gavuzzo, E; Giorgi, R; Mazza, F; Pantaleoni, G, 1988) |
| " Cetyl GABA, sodium and lithium hydroxybutyrates and phenibut were shown to be able to decrease the retrograde amnesia caused by electroshock in passive avoidance performance." | 3.67 | [Nootropic properties of gamma-aminobutyric acid derivatives]. ( Ostrovskaia, RU; Trofimov, SS, 1984) |
| "The effects of piracetam on the amnesias induced by scopolamine, diazepam and electroconvulsive shock (ECS) were studied in a passive avoidance procedure in the mouse and compared with the interactions of piracetam with the major behavioral effects of these treatments, namely scopolamine-induced hyperactivity, diazepam-induced release of punished behavior (Four Plates Test) and ECS-induced convulsions." | 3.67 | Specificity of piracetam's anti-amnesic activity in three models of amnesia in the mouse. ( Avril, I; Chermat, R; Lenègre, A; Porsolt, RD; Stéru, L, 1988) |
| "The effects of exifone (ADLONE), hexahydro-2,3,4,3',4',5'-benzophenone, were tested in two models of memory in the mouse: habituation of exploratory activity and antagonism of amnesia induced by scopolamine in a passive avoidance task." | 3.67 | The effects of exifone, a new agent for senile memory disorder, on two models of memory in the mouse. ( Avril, I; Doumont, G; Lenègre, A; Porsolt, RD; Stéru, L, 1987) |
| "Dementia is one of the age related mental problems and a characteristic symptom of various neurodegenerative disorders including Alzheimer's disease." | 1.33 | Evaluation of nootropic potential of Ocimum sanctum Linn. in mice. ( Joshi, H; Parle, M, 2006) |
| "3 and 1 mg/kg ip for most compounds), the presence of a bell-shaped dose-response curve and, generally, a reduction of biological activity after po administration." | 1.29 | Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers. ( Banfi, S; Biagetti, R; Cerri, A; Dorigotti, L; Farina, C; Magnani, M; Pfeiffer, U; Pinza, M; Pozzi, O; Riccaboni, MT, 1993) |
| " Active compounds exhibited an inverted U-shaped dose-response curve." | 1.27 | Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam. ( Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (21.28) | 18.7374 |
| 1990's | 14 (29.79) | 18.2507 |
| 2000's | 10 (21.28) | 29.6817 |
| 2010's | 12 (25.53) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Altomare, C | 1 |
| Carotti, A | 1 |
| Casini, G | 1 |
| Cellamare, S | 1 |
| Ferappi, M | 1 |
| Gavuzzo, E | 1 |
| Mazza, F | 1 |
| Pantaleoni, G | 1 |
| Giorgi, R | 1 |
| Butler, DE | 1 |
| Nordin, IC | 1 |
| L'Italien, YJ | 1 |
| Zweisler, L | 1 |
| Poschel, PH | 1 |
| Marriott, JG | 1 |
| Angelucci, L | 1 |
| Calvisi, P | 1 |
| Catini, R | 1 |
| Cosentino, U | 1 |
| Cozzolino, R | 1 |
| De Witt, P | 1 |
| Ghirardi, O | 1 |
| Giannessi, F | 1 |
| Giuliani, A | 1 |
| Guaraldi, D | 1 |
| Manetti, D | 5 |
| Ghelardini, C | 5 |
| Bartolini, A | 3 |
| Bellucci, C | 1 |
| Dei, S | 5 |
| Galeotti, N | 2 |
| Gualtieri, F | 2 |
| Romanelli, MN | 5 |
| Scapecchi, S | 4 |
| Teodori, E | 5 |
| Martini, E | 3 |
| Guandalini, L | 4 |
| Geronikaki, AA | 1 |
| Dearden, JC | 1 |
| Filimonov, D | 1 |
| Galaeva, I | 1 |
| Garibova, TL | 1 |
| Gloriozova, T | 1 |
| Krajneva, V | 1 |
| Lagunin, A | 1 |
| Macaev, FZ | 1 |
| Molodavkin, G | 1 |
| Poroikov, VV | 1 |
| Pogrebnoi, SI | 1 |
| Shepeli, F | 1 |
| Voronina, TA | 3 |
| Tsitlakidou, M | 1 |
| Vlad, L | 1 |
| Di Cesare Mannelli, L | 3 |
| Bartolucci, G | 2 |
| Bertucci, C | 1 |
| Martino, MV | 1 |
| Melani, F | 1 |
| Malik, R | 1 |
| Floriddia, E | 1 |
| Orlandi, F | 1 |
| Kandeda, AK | 1 |
| Nodeina, S | 1 |
| Mabou, ST | 1 |
| Ukai, K | 2 |
| Watanabe, M | 2 |
| Zvejniece, L | 1 |
| Vavers, E | 1 |
| Svalbe, B | 1 |
| Vilskersts, R | 1 |
| Domracheva, I | 1 |
| Vorona, M | 1 |
| Veinberg, G | 1 |
| Misane, I | 1 |
| Stonans, I | 1 |
| Kalvinsh, I | 1 |
| Dambrova, M | 1 |
| Zhiliuk, VI | 1 |
| Mamchur, VI | 1 |
| Pavlov, SV | 1 |
| Fujishiro, H | 1 |
| Kosaka, K | 1 |
| Ozaki, N | 1 |
| Yasnetsov, VV | 2 |
| Tsublova, EG | 1 |
| Skachilova, SY | 1 |
| Karsanova, SK | 1 |
| Ivanov, YV | 1 |
| Pandey, S | 1 |
| Garabadu, D | 1 |
| Nahata, A | 1 |
| Patil, UK | 1 |
| Dixit, VK | 1 |
| Reyes, A | 1 |
| Huerta, L | 1 |
| Alfaro, M | 1 |
| Navarrete, A | 1 |
| Bakker, A | 1 |
| Krauss, GL | 1 |
| Albert, MS | 1 |
| Speck, CL | 1 |
| Jones, LR | 1 |
| Stark, CE | 1 |
| Yassa, MA | 1 |
| Bassett, SS | 1 |
| Shelton, AL | 1 |
| Gallagher, M | 1 |
| Piplani, P | 1 |
| Singh, P | 1 |
| Sharma, A | 1 |
| Kumar, V | 1 |
| Khanna, VK | 1 |
| Seth, PK | 1 |
| Singh, PN | 1 |
| Bhattacharya, SK | 2 |
| Parle, M | 2 |
| Dhingra, D | 1 |
| Joshi, H | 1 |
| Ostrovskaia, RU | 2 |
| Trofimov, SS | 2 |
| Firova, FA | 1 |
| Israel, L | 1 |
| Melac, M | 1 |
| Milinkevitch, D | 1 |
| Dubos, G | 1 |
| Akhundov, RA | 2 |
| Sultanov, AA | 1 |
| Gadzhily, RA | 1 |
| Sadykhov, RV | 1 |
| Melikov, EM | 1 |
| Serkerov, SV | 1 |
| Movsumov, GD | 1 |
| Mir-Babaev, NF | 1 |
| Upadhyay, SN | 1 |
| Jaiswal, AK | 1 |
| Pinza, M | 1 |
| Farina, C | 1 |
| Cerri, A | 1 |
| Pfeiffer, U | 1 |
| Riccaboni, MT | 1 |
| Banfi, S | 1 |
| Biagetti, R | 1 |
| Pozzi, O | 1 |
| Magnani, M | 1 |
| Dorigotti, L | 1 |
| Pan, JC | 1 |
| Zhang, SS | 1 |
| Genkova-Papazova, MG | 1 |
| Lazarova-Bakarova, MB | 1 |
| Lee, SC | 1 |
| Moon, YS | 1 |
| You, KH | 1 |
| Andreani, A | 1 |
| Leoni, A | 1 |
| Locatelli, A | 1 |
| Morigi, R | 1 |
| Rambaldi, M | 1 |
| Pietra, C | 1 |
| Villetti, G | 1 |
| Malmberg-Aiello, P | 1 |
| Ipponi, A | 1 |
| Schunack, W | 1 |
| Chopin, P | 1 |
| Briley, M | 1 |
| Burov, IuV | 1 |
| Robakidze, TN | 1 |
| Kadysheva, LV | 1 |
| Voronin, AE | 1 |
| Shaposhnikova, GI | 1 |
| Mondadori, C | 1 |
| Etienne, P | 1 |
| Zagorevskiĭ, VA | 1 |
| Mosharrof, AH | 2 |
| Petkov, VD | 2 |
| Rakhmankulova, IKh | 1 |
| Sprints, AM | 1 |
| Lenègre, A | 2 |
| Chermat, R | 1 |
| Avril, I | 2 |
| Stéru, L | 2 |
| Porsolt, RD | 2 |
| Doumont, G | 1 |
| Lasarova, MB | 1 |
| Markovska, VL | 1 |
| Petkov, VV | 1 |
| Piercey, MF | 1 |
| Vogelsang, GD | 1 |
| Franklin, SR | 1 |
| Tang, AH | 1 |
| Spignoli, G | 1 |
| Pepeu, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861] | Phase 2 | 26 participants (Actual) | Interventional | 2019-04-11 | Completed | ||
| Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease[NCT03617497] | 78 participants (Actual) | Interventional | 2020-12-01 | Active, not recruiting | |||
| Neuroimaging Epigenetics of Prospective Postpartum Depression Biomarkers[NCT03638687] | 80 participants (Anticipated) | Observational | 2014-05-31 | Completed | |||
| Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability[NCT02002819] | Phase 2 | 34 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo
| Intervention | Pearson coefficient (Median) |
|---|---|
| AGB101 220 mg | 0.233 |
| Placebo | 0.318 |
Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test
| Intervention | score on a scale (Mean) |
|---|---|
| AGB101 220 mg | 108 |
| Placebo | 105 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | -1.0 |
| Placebo (Epileptiform Activity) | 1.5 |
Blood samples intended for Quest Diagnostics LEV and prolactin serum levels (one 6 mL tube) will be processed in the following manner, as outlined in the Quest Diagnostics lab manual. The whole blood will be allowed to clot for 60 minutes and centrifuged at 2200 - 2500 revolutions per minute (RPM) for at least 15 minutes. The resulting serum will be split into 2 cryovials which will be stored at -20°C and immediately shipped for external assessment of LEV and prolactin levels. Prolactin will be assessed via immunoassay. The concentration of LEV in serum will be measured using validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) methods. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | ng/mL (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.2 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.2 |
| Placebo | 0.8 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) - The ADCS-ADL rating instrument (Galasko et al. 1997) will be used to evaluate functional capacity. The ADCS-ADL is a caregiver rated questionnaire. Scores on the 24-item ADCS-ADL range from 0 to 78. A higher score indicates less severity while a lower score indicates greater severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.4 |
| Placebo | 0.3 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) - The ADCS-CGIC is a seven-point scale that gives a global rating of change from baseline (Schneider et al. 1997). The baseline and follow up assessments are based on interviews with the subject and the informant. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 4.0 |
| Placebo | 4.0 |
Neuropsychiatric Inventory (NPI) - The NPI (Cummings et al. 1994) will be used to evaluate the severity of behavioral symptoms. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.8 |
| Placebo | 0.2 |
A 20-minute computer-based virtual navigation test will be used to assess how well a subject can navigate a virtual community to reach a goal destination. The subjects will then be measured on their ability to accurately navigate the virtual community after a period of a few hours. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | correct turns (Mean) |
|---|---|
| No Epileptiform Activity | -6.0 |
| Epileptic Activity | 17.4 |
"Epileptiform activity will be measured using a 1-hr resting magnetoencephalogram/electroencephalogram (M/EEG). M/EEG can detect abnormal epileptiform findings called spikes. The M/EEG will be read by an epileptologist with specialized training to assess whether there are any spikes. If spikes are observed during the M/EEG they will be counted to determine their frequency (e.g., 5 spikes per 1 hour recording). The frequency of spikes will then be compared to baseline values from before beginning the study treatment, using statistical tests to determine if the frequency changed with treatment." (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | Epileptiform events (Mean) |
|---|---|
| Levetiracetam | -0.1 |
| Placebo | -0.2 |
Changes in executive function were measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: antisaccade , set shifting , flanker task, dot counting, spatial 1-back, category fluency, and letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory. For this study, scores with SEs greater than 0.55 were classified as unreliable and excluded from analysis. Composite scores from 2 participants were excluded on this basis.The EXAMINER ranges for the participants in the study were -2.59 to 1.33. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.06 |
| Placebo | -0.14 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 1.5 |
| Placebo | -1.4 |
Clinical Dementia Rating Sum of Boxes (CDR-SOB) - The CDR will be used as a global measure of dementia severity (Morris 1993). The CDR consists of questions addressed to the caregiver/informant. The lowest score one can receive is a 0 and the highest is a 3. Score is measured by getting the mean of the individual scores in each category. Lower scores equate to less dementia severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.1 |
Changes in executive function will be measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: NIH EXAMINER - antisaccade , NIH EXAMINER - set shifting , NIH EXAMINER - flanker task, NIH EXAMINER - dot counting, NIH EXAMINER - spatial 1-back, NIH EXAMINER - category fluency, and NIH EXAMINER - letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory (Kramer et al. J Int Neuropsychol Soc. 2014;20(1):11-19. doi:10.1017/S1355617713001094). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| No Epileptiform Activity | -0.01 |
| Epileptiform Activity | 0.22 |
The One Day Fluctuation Assessment Scale will be used to quantitate fluctuations of dementia symptoms (Walker et al. 2000). The One Day Fluctuation Assessment Scale has a score range of 0-21 points,with higher scores indicatingmore fluctuations. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.3 |
| Placebo | -0.4 |
Two standardized methods will be used to quantitate fluctuations of dementia symptoms: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale (Walker et al. 2000). : The Clinician Assessment of Fluctuation (score range,0-12 points, with higher scores indicating more fluctuations),26 the One Day Fluctuation Assessment Scale (score range,0-21 points, with higher scores indicatingmore fluctuations). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.9 |
| Placebo | 0.1 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. The mean below represents the average change in score between the timepoints for all participants. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | 4.7 |
| Placebo (Epileptiform Activity) | -2.6 |
2 trials available for piracetam and Amnesia
| Article | Year |
|---|---|
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amnesia; Brain Mapping; Case-Control Studies; Choice Behavior; Cognitive Dy | 2012 |
Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment.
Topics: Aged; Amnesia; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, | 1994 |
45 other studies available for piracetam and Amnesia
| Article | Year |
|---|---|
Synthesis and cognition activating properties of some mono- and bicyclic lactam derivatives.
Topics: Amnesia; Animals; Avoidance Learning; Behavior, Animal; Bridged Bicyclo Compounds; Bridged-Ring Comp | 1988 |
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
Topics: Amnesia; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electroshock; Huma | 1984 |
Synthesis and amnesia-reversal activity of a series of 7- and 5-membered 3-acylamino lactams.
Topics: Amnesia; Animals; Brain; Cholinesterase Inhibitors; Drug Design; Electroshock; In Vitro Techniques; | 1993 |
Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents.
Topics: Adrenergic alpha-Agonists; Amnesia; Animals; Avoidance Learning; Baclofen; Clonidine; Dose-Response | 2000 |
4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs.
Topics: Amnesia; Animals; Avoidance Learning; Chemical Phenomena; Chemistry, Physical; Cognition; Dose-Respo | 2003 |
Design of new cognition enhancers: from computer prediction to synthesis and biological evaluation.
Topics: Amnesia; Animals; Avoidance Learning; Computer Simulation; Drug Design; Male; Nootropic Agents; Oxaz | 2004 |
Synthesis and biological evaluation of 3,7-diazabicyclo[4.3.0]nonan-8-ones as potential nootropic and analgesic drugs.
Topics: Amnesia; Analgesics; Animals; Behavior, Animal; Drug Design; Ketones; Mice; Nootropic Agents; Scopol | 2011 |
Influence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootropic drugs.
Topics: Adjuvants, Anesthesia; Amnesia; Animals; Avoidance Learning; Cognition; Drug Design; Mice; Nootropic | 2012 |
Substituted piperazines as nootropic agents: 2- or 3-phenyl derivatives structurally related to the cognition-enhancer DM235.
Topics: Amnesia; Animals; Avoidance Learning; Mice; Nootropic Agents; Piperazines; Pyrroles; Stereoisomerism | 2015 |
An aqueous extract of Syzygium cumini protects against kainate-induced status epilepticus and amnesia: evidence for antioxidant and anti-inflammatory intervention.
Topics: Amnesia; Animals; Anti-Inflammatory Agents; Anticonvulsants; Antioxidants; Kainic Acid; Mice; Pirace | 2022 |
Transient epileptic amnesia without epileptic seizures: proposal of a new entity.
Topics: Amnesia; Anticonvulsants; Electroencephalography; Epilepsy; Humans; Levetiracetam; Male; Middle Aged | 2017 |
The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors.
Topics: Acetamides; Allosteric Regulation; Amnesia; Animals; Behavior, Animal; Brain; Calcium Signaling; Cel | 2014 |
[Role of functional state of neuronal mitochondria of cerebral cortex in mechanisms of nootropic activity of neuroprotectors in rats with alloxan hyperglycemia].
Topics: Alloxan; Amnesia; Animals; Avoidance Learning; Cerebral Cortex; Cognition; Cytidine Diphosphate Chol | 2015 |
Similarity of symptoms between transient epileptic amnesia and Lewy body disease.
Topics: 3-Iodobenzylguanidine; Aged; Amnesia; Anticonvulsants; Cognition Disorders; Electroencephalography; | 2017 |
[STUDYING SOME PHARMACOLOGICAL EFFECTS OF NEW 3-HYDROXYPYRIDINE DERIVATIVE].
Topics: Adamantane; Amnesia; Animals; Animals, Outbred Strains; Anticonvulsants; Benzimidazoles; Brain Ische | 2016 |
Piracetam Facilitates the Anti-Amnesic but not Anti-Diabetic Activity of Metformin in Experimentally Induced Type-2 Diabetic Encephalopathic Rats.
Topics: Amnesia; Animals; Blood Glucose; Brain Diseases; Brain-Derived Neurotrophic Factor; Choline; Diabete | 2017 |
Effect of Convulvulus pluricaulis Choisy. on learning behaviour and memory enhancement activity in rodents.
Topics: Amnesia; Animals; Convolvulaceae; Disease Models, Animal; Dose-Response Relationship, Drug; Medicine | 2008 |
Synthesis and nootropic activity of some 2,3-dihydro-1H-isoindol-1-one derivatives structurally related with piracetam.
Topics: Amnesia; Animals; Behavior, Animal; Isoindoles; Mice; Nootropic Agents; Piracetam; Scopolamine; Ster | 2010 |
Synthesis, molecular docking and antiamnesic activity of selected 2- naphthyloxy derivatives.
Topics: Amnesia; Animals; Cholinesterase Inhibitors; Enzyme Activation; Glycolates; Hydrogen Bonding; Ligand | 2013 |
Brain neurotransmitter receptor binding and nootropic studies on Indian Hypericum perforatum Linn.
Topics: Amnesia; Animals; Avoidance Learning; Behavior, Animal; Binding, Competitive; Brain; Dose-Response R | 2002 |
Ascorbic Acid: a promising memory-enhancer in mice.
Topics: Aging; Amnesia; Animals; Antioxidants; Anxiety; Ascorbic Acid; Avoidance Learning; Behavior, Animal; | 2003 |
Evaluation of nootropic potential of Ocimum sanctum Linn. in mice.
Topics: Alzheimer Disease; Amnesia; Animals; Dementia; Diazepam; Dose-Response Relationship, Drug; Humans; M | 2006 |
[Nootropic properties of gamma-aminobutyric acid derivatives].
Topics: Amnesia; Amnesia, Retrograde; Animals; Avoidance Learning; Baclofen; Butyrates; Conditioning, Classi | 1984 |
[Persistent aftereffect of the amnestic effect of scopolamine in rats and correction with piracetam].
Topics: Amnesia; Animals; Learning; Male; Memory; Piracetam; Rats; Rats, Wistar; Scopolamine | 1995 |
[Psychoregulating role of nicotinamide].
Topics: Amnesia; Animals; Anti-Anxiety Agents; Anticonvulsants; Male; Memory Disorders; Mice; Neurotic Disor | 1993 |
[The sesquiterpene lactone "azerin" has memory enhancing properties].
Topics: Amnesia; Animals; Avoidance Learning; Lactones; Male; Piracetam; Placebos; Rats; Sesquiterpenes | 1993 |
Effect of piracetam on electroshock induced amnesia and decrease in brain acetylcholine in rats.
Topics: Acetylcholine; Amnesia; Animals; Brain; Electroshock; Male; Memory; Piracetam; Rats; Rats, Wistar; S | 1993 |
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.
Topics: Amnesia; Animals; Avoidance Learning; Cognition; Imidazoles; Male; Mice; Molecular Structure; Pirace | 1993 |
[Antagonism of piracetam on the amnestic effect of diazepam in mice].
Topics: Amnesia; Animals; Diazepam; Female; Learning; Male; Memory; Mice; Neuroprotective Agents; Piracetam | 1996 |
Piracetam and fipexide prevent PTZ-kindling-provoked amnesia in rats.
Topics: Amnesia; Animals; Avoidance Learning; Kindling, Neurologic; Male; Pentylenetetrazole; Piperazines; P | 1996 |
Effects of red ginseng saponins and nootropic drugs on impaired acquisition of ethanol-treated rats in passive avoidance performance.
Topics: alpha-Methyltyrosine; Amnesia; Animals; Avoidance Learning; Dose-Response Relationship, Drug; Drug I | 2000 |
4-Aminopyridine derivatives with antiamnesic activity.
Topics: 4-Aminopyridine; Alzheimer Disease; Aminopyridines; Amnesia; Animals; Avoidance Learning; Carbon Dio | 2000 |
Antiamnesic effect of metoprine and of selective histamine H(1) receptor agonists in a modified mouse passive avoidance test.
Topics: Amnesia; Animals; Avoidance Learning; Enzyme Inhibitors; Histamine; Histamine Agonists; Histamine H1 | 2000 |
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats.
Topics: Amnesia; Animals; Avoidance Learning; Cognition; Dihydroergotoxine; Dose-Response Relationship, Drug | 1992 |
[Study of anti-amnesic activity of amiridin in a model of amnesic syndrome].
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Amnesia; Animals; Cerebral Cortex; Choline | 1991 |
Nootropic effects of ACE inhibitors in mice.
Topics: Adrenalectomy; Amnesia; Angiotensin-Converting Enzyme Inhibitors; Animals; Avoidance Learning; Behav | 1990 |
[Nootropic activity of nicotinamide and its structural analogs].
Topics: Amnesia; Animals; Hypoxia; Male; Meclofenoxate; Mice; Niacinamide; Piracetam; Psychotropic Drugs; Py | 1990 |
Effects of citicholine and of the combination citicholine + piracetam on the memory (experiments on mice).
Topics: Amnesia; Animals; Avoidance Learning; Choline; Cytidine Diphosphate Choline; Male; Memory; Mice; Mod | 1990 |
[Pharmacological analysis of memory disorders of different origins].
Topics: Amnesia; Animals; Anti-Anxiety Agents; Avoidance Learning; Benzodiazepines; Benzodiazepinones; Condi | 1989 |
[The mechanisms of memory disorders at the stages in its acquisition and fixation].
Topics: Amnesia; Animals; Avoidance Learning; Conditioning, Classical; Dose-Response Relationship, Drug; Fem | 1988 |
Specificity of piracetam's anti-amnesic activity in three models of amnesia in the mouse.
Topics: Amnesia; Animals; Avoidance Learning; Diazepam; Drug Interactions; Electroshock; Male; Memory; Mice; | 1988 |
The effects of exifone, a new agent for senile memory disorder, on two models of memory in the mouse.
Topics: Amnesia; Animals; Avoidance Learning; Benzophenones; Dementia; Exploratory Behavior; Habituation, Ps | 1987 |
Effect of piracetam and of standardized ginseng extract on the electroconvulsive shock-induced memory disturbances in "step-down" passive avoidance.
Topics: Amnesia; Amnesia, Retrograde; Animals; Avoidance Learning; Conditioning, Classical; Electroshock; Ma | 1987 |
Reversal of scopolamine-induced amnesia and alterations in energy metabolism by the nootropic piracetam: implications regarding identification of brain structures involved in consolidation of memory traces.
Topics: Amnesia; Animals; Autoradiography; Avoidance Learning; Brain; Carbon Radioisotopes; Deoxyglucose; El | 1987 |
Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia.
Topics: Acetylcholine; Amnesia; Animals; Avoidance Learning; Brain; Cerebral Cortex; Choline; Electroshock; | 1986 |